
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics Inc. has demonstrated promising clinical improvements in its therapeutic programs, particularly with DYNE-251, which has shown sustained enhancements in key clinical endpoints, including the North Star Ambulatory Assessment (NSAA) and timed walking tests. The company's FORCE platform exhibits potential advantages in delivering targeted therapeutics, which may enhance treatment outcomes for neuromuscular diseases, notably with a successful increase in dystrophin expression as indicated by a 3.27% increase in exon 51 skipping. Additionally, the favorable safety profile of DYNE-251, with no significant increases in treatment-related adverse events, underscores the potential for regulatory approval, positioning the company favorably within the biotech landscape.
Bears say
Dyne Therapeutics faces several challenges that contribute to a negative outlook on its stock. The results of ongoing and future clinical trials for its RNA-based therapeutics present significant risk; failures to achieve clinical endpoints can lead to substantial downward pressure on share prices. Additionally, high patient discontinuation rates, coupled with advancements in competitive treatment methods and potential issues surrounding intellectual property protection, further jeopardize the company’s market position and overall viability.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares